Charlottesville, VANCT07507708Now EnrollingIRB Ready

Type 1 Diabetes (T1D) Clinical Trial in Charlottesville, VA

Access cutting-edge type 1 diabetes (t1d) treatment through this clinical trial at a research site in Charlottesville. Study-provided care at no cost to qualified participants.

Sponsored by Sue Brown

Quick Self-Assessment

See if you qualify for this Charlottesville location

Preparing your pre-screening questions…

Expert Care in Charlottesville

Access type 1 diabetes (t1d) specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related type 1 diabetes (t1d) treatment provided free

Apply for This Charlottesville Location

Check if you qualify for this type 1 diabetes (t1d) clinical trial in Charlottesville, VA

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Charlottesville

    Convenient for VA residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Charlottesville site if eligible
  4. 4Begin participation

About This Type 1 Diabetes (T1D) Study in Charlottesville

This study is a randomized cross-over trial comparing AIDANET with Anticipation to AIDANET in FCL without Anticipation. Participants will complete 4 weeks of AID data collection which will be used to establish baseline and initialize the control algorithm. Participants will then be randomized to one of two groups: Group A: AIDANET in FCL with Anticipation (AIDANET+ACL), and Group B: AIDANET in FCL without Anticipation (AIDANET+FCL). The study duration of each group is 4 weeks each. The order of these two phases will be dependent upon randomization.

Sponsor: Sue Brown

Who Can Participate

Inclusion Criteria

Age ≥18.0 years old at time of consent
Clinical diagnosis, based on investigator assessment, of T1D for \> 1 year.
Having used an FDA approved AID system within the last 6 months (can be intermittent use).
Currently using insulin for \>6 months.
Willingness to switch to use an FDA-approved personal insulin for the study pump (e.g., lispro or aspart, or biosimilar FDA-approved products) as directed by the study team.
Has one or more supportive companions knowledgeable about emergency procedures for severe hypoglycemia and able to contact emergency services and study staff who either lives with participant or located within approximately 30 minutes of participant and able to locate participant in the event of an emergency.
Participant not currently known to be pregnant or breastfeeding.
If participant can become pregnant, they must agree to use a form of contraception to prevent pregnancy while a participant in the study. A negative serum or urine pregnancy test will be required for all participants of childbearing potential. Participants who become pregnant will be discontinued from the study. Also, participants who during the study develop and express the intention to become pregnant within the timespan of the study will be discontinued.
Willingness to wear a Dexcom CGM during each of the study phases.
Willingness to use the study AIDANET system (CGM, pump, and phone) during the relevant study periods.
Willingness not to start any new non-insulin glucose-lowering agent during the trial.
Willingness to participate in all study procedures including in person training.
Access to internet at home and willingness to upload data during the study as needed.
Investigator has confidence that the participant can successfully operate all study devices and can adhere to the protocol.
Participant is proficient in reading and verbal communication in English. Participant

Exclusion Criteria

The participant must not have any exclusion criteria to be eligible to participate in the study.
Plans to start a new non-insulin glucose-lowering agent (e.g., GLP-1 receptor agonists, Symlin, DPP-4 inhibitors,). Participants may be on a stable dose of such an agent for at least the past month.
Current use of sulfonylurea medications.
Uncontrolled microvascular complications such as active proliferative retinopathy not being treated or not responsive to current treatment.
Current use of an SGLT-2 or SGLT-1/2 inhibitor due to risk of euglycemic DKA.
Hemophilia or any other bleeding disorder.
History of severe hypoglycemic events with seizure or loss of consciousness in the last 12 months.
History of DKA event in the last 12 months.
Currently on peritoneal or hemodialysis.
Currently being treated for adrenal insufficiency.
Currently being treated for a seizure disorder.
Hypothyroidism or hyperthyroidism that is not adequately treated.
Use of oral or injectable steroids at the time of enrollment.
Known ongoing adhesive intolerance that is not well managed.
A condition, which in the opinion of the investigator or designee, would put the participant or study at risk.
Participation in another interventional trial at the time of enrollment.
Participant with a direct supervisor at work/school who is involved in the conduct of the trial.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Charlottesville?

Yes, this clinical trial (NCT07507708) has an active research site in Charlottesville, VA that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Type 1 Diabetes (T1D) Treatment Options in Charlottesville, VA

If you're searching for type 1 diabetes (t1d) treatment options in Charlottesville, VA, this clinical trial (NCT07507708) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Charlottesville research site is actively enrolling participants for this clinical trial. You'll receive care from experienced type 1 diabetes (t1d) specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all type 1 diabetes (t1d) clinical trials near you to find additional studies recruiting in your area.

More Pulmonary Embolism Trials in Charlottesville, VA

See all pulmonary embolism clinical trials recruiting in Charlottesville — not just this study.

Browse Pulmonary Embolism Trials in Charlottesville →

Ready to Join in Charlottesville?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Charlottesville, VA